- Topic
30k Popularity
45k Popularity
11k Popularity
315 Popularity
2k Popularity
4k Popularity
67k Popularity
138k Popularity
114 Popularity
1748k Popularity
- Pin
- Welcome Kevin_Lee to the Gate Square! 🎉
Looking forward to more great crypto insights from him.
Check out and engage with Kevin_Lee’s latest post!
👉 Post: https://www.gate.com/post/status/11758920
👉 Profile: https://www.gate.com/profile/Kevin%20Lee
Let’s give Kevin_Lee a warm welcome! 👏👏👏
- 🎯 LOT Newcomer Limited-Time Airdrop is Live!
Individual users can earn up to 1,000 LOT — share from a total prize pool of 1,000,000 LOT!
🏃 Join now: https://www.gate.com/campaigns/1294
Complete deposit and trading tasks to receive random LOT airdrops. Exclusive Alpha trading task await!🎯 LOT Newcomer Limited-Time Airdrop is Live!
Individual users can earn up to 1,000 LOT — share from a total prize pool of 1,000,000 LOT!
🏃 Join now: https://www.gate.com/campaigns/1294
Complete deposit and trading tasks to receive random LOT airdrops. Exclusive Alpha trading task await!
- 🎯 How to Earn Content Mining Rewards on Gate Post?
1️⃣ Create a post on Gate Post
2️⃣ Get likes or comments from other users
3️⃣ If those users trade (spot or futures) shortly after engaging with your post...
💰 You earn up to 10% commission on their trading fees!
📢 Share ✍️ Engage 💬 Earn 💰
- 🚀 Gate Square Creator Spark Program is Live!
We're officially recruiting the first batch of creators on Gate Square! Whether you're a crypto KOL, project team, or media outlet, join now and enjoy:
💰 Over $10,000 in monthly posting rewards
📣 Exposure to millions of Gate users
📢 Featured promotion and official support
🔥 Don't miss this early-mover advantage — apply now 👉 https://www.gate.com/questionnaire/6819
📄 More info 👉 https://www.gate.com/announcements/article/45695 - 🎉 Gate Alpha Second Points Special Airdrop is coming!
Get Token Mystery Boxes based on your Alpha Points - No points will be deducted.
📸 Alpha Points Snapshot: June 24, 16:00 (UTC)
Multi-chain trading now supported — buy on-chain assets directly with USDT!
🔗 Full details: https://www.gate.com/announcements/article/45683
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.